Letter Services Article: Active Reference - Nuclear Medicine

Nov 19, 2007
AuntMinnie Service

Your online source for the
latest information about
Nuclear Medicine
  • Updated monthly
  • Timely, accurate, concise
  • A free resource from your friends at AM
    • Visit the AuntMinnie.com
    Nuclear Medicine Active Reference
    Section Today!
     nuclearmedicine.auntminnie.com
    Latest in Nuclear Radiology
    Rise Of Thernostics Part 6 Thumbnail
    The rise of theranostics: Part 6 -- Private practices pivot to clinical trials
    September 12, 2025
    A conceptual framework for neurotheranostics.
    ARRS: 'Neurotheranostics' may be new frontier for nuclear medicine
    April 29, 2025
    Pet Ct Machine
    ARRS: Rib uptake evaluation on F-18 DCFPyL PET/CT presents challenges
    April 28, 2025
    Patient examples of SPECT/CT and PET/CT RECIP 1.0. (A) SPECT and PET maximum-intensity projection (MIP) images in 74-year-old man with mCRPC. Serum PSA level at baseline was 449 ng/mL and slightly increased to 525 ng/mL after two cycles of Lu-177 PSMA. Eastern Cooperative Oncology Group (ECOG) score was 2 at baseline and increased to 3 after 2 cycles. The patient was classified by readers as RECIP-progressive disease on both SPECT and PET. Overall survival was 4.7 months. Two cycles of Lu-177 PSMA were administered. (B) SPECT and PET MIP images in 74-year-old man with mCRPC. Serum PSA level was 231 ng/mL at baseline and decreased to 12.5 ng/mL after 2 cycles of Lu-177 PSMA. ECOG score was less than 2 at baseline and after 2 cycles of Lu-177 PSMA. The patient was classified by readers as RECIP-partial response on both SPECT and PET. Overall survival was 14.3 months. Four cycles of Lu-177 PSMA were administered.
    SPECT/CT predicts overall survival in Pluvicto patients
    April 25, 2025
    Related Stories
    187x200 Am Logo
    Companies
    AuntMinnie.com
    2007 11 14 15 34 50 706
    Molecular Imaging
    FDG-PET works for nose cancer staging, study finds
    2007 10 22 14 14 29 706
    Nuclear Medicine
    MedX
    2007 10 16 10 45 47 706
    Nuclear Medicine
    AuntMinnie.com MarketStat #49: Budgets for nuclear medicine radiopharmaceuticals
    More in Nuclear Radiology
    The rise of theranostics: Part 6 -- Private practices pivot to clinical trials
    By Liz Carey
    Regional capacity slowly builds for burgeoning demand, but data is lacking on nuclear medicine and theranostics needs across the U.S.
    September 12, 2025
    Rise Of Thernostics Part 6 Thumbnail
    ARRS: 'Neurotheranostics' may be new frontier for nuclear medicine
    By Will Morton
    Advances in brain PET imaging combined with new treatments for Alzheimer’s have given rise to a new concept of "neurotheranostics."
    April 29, 2025
    A conceptual framework for neurotheranostics.
    ARRS: Rib uptake evaluation on F-18 DCFPyL PET/CT presents challenges
    By Maryam Payne
    Evaluating increased rib uptake on F-18 DCFPyL PET/CT in prostate cancer patients may lead to false positives.
    April 28, 2025
    Pet Ct Machine
    SPECT/CT predicts overall survival in Pluvicto patients
    By Will Morton
    New evidence supports using SPECT/CT scans along with serum PSA levels to evaluate early patient responses to Pluvicto treatment.
    April 25, 2025
    Patient examples of SPECT/CT and PET/CT RECIP 1.0. (A) SPECT and PET maximum-intensity projection (MIP) images in 74-year-old man with mCRPC. Serum PSA level at baseline was 449 ng/mL and slightly increased to 525 ng/mL after two cycles of Lu-177 PSMA. Eastern Cooperative Oncology Group (ECOG) score was 2 at baseline and increased to 3 after 2 cycles. The patient was classified by readers as RECIP-progressive disease on both SPECT and PET. Overall survival was 4.7 months. Two cycles of Lu-177 PSMA were administered. (B) SPECT and PET MIP images in 74-year-old man with mCRPC. Serum PSA level was 231 ng/mL at baseline and decreased to 12.5 ng/mL after 2 cycles of Lu-177 PSMA. ECOG score was less than 2 at baseline and after 2 cycles of Lu-177 PSMA. The patient was classified by readers as RECIP-partial response on both SPECT and PET. Overall survival was 14.3 months. Four cycles of Lu-177 PSMA were administered.
    PET/CT visualizes extremely rare brain inflammation
    By Will Morton
    An F-18 FDG-PET/CT scan proved crucial in identifying an ultrarare case of brain inflammation in a patient due to the flu.
    March 27, 2025
    Brain MRI and F-18 FDG brain and whole-body PET/CT images. (A) No obvious abnormalities were found in axial and sagittal slices from T2-weighted MR images. (B) Whole cerebellar cortex had diffuse F-18 FDG hypermetabolism in PET/CT brain images, with SUVmax of 25.91. (C and D) Whole-body F-18 FDG-PET/CT showing distended bladder. TLG = total lesion glycolysis; MTV = metabolic tumor volume. Image and caption courtesy of the Journal of Nuclear Medicine.
    Hermes Medical Solutions updates dosimetry software
    By AuntMinnie.com staff writers
    Hermes Medical Solutions has updated and released its Hermia Voxel Dosimetry software.
    October 15, 2024
    Ame 2018 12 11 00 02 7009 Atom Nuclear Lab 400
    The rise of theranostics: Part 5 -- Advice from center administrators
    By Liz Carey
    Want to launch theranostics at your hospital and cancer center? An SNMMI 2024 session provided key planning steps.
    July 12, 2024
    Nuclear medicine technologist and theranostics practice administrator Dmitry Beyder (left) and Vikas Prasad, MD, PhD (right), lead the theranostics center at Barnes-Jewish Hospital/Washington University in Saint Louis, MO. Image courtesy of Washington University.
    The rise of theranostics: Part 3 -- What is a theranostics center?
    By Liz Carey
    For this third in a series covering the rise of theranostics, AuntMinnie.com asked four doctors of theranostics to discuss the spectrum of freestanding theranostics center development.
    June 3, 2024
    Part3 Riseof Thernaostics Cover
    Evergreen Theragnostics raises $26M
    By AuntMinnie.com staff writers
    Evergreen Theragnostics has completed a $26 million capital raise through its existing shareholders and new backers Petrichor and LIFTT.
    April 19, 2024
    Money Bills 400
    IMV: Nuclear medicine procedure volumes decrease
    By Davin Korstjens
    Total nuclear medicine patient study volumes decreased between 2021 and 2023, according to a newly published IMV 2024 Nuclear Medicine Market Outlook Report.
    April 15, 2024
    Scientist Atom Molecule
    Life Molecular Imaging, Sofie add Neuraceq availability out of Ohio
    By AuntMinnie.com staff writers
    Life Molecular Imaging and Sofie Biosciences have begun offering the Neuraceq PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio.
    April 5, 2024
    Brain Puzzle Dementia Social
    RSNA calls out toxicity concerns with theranostics
    By AuntMinnie.com staff writers
    RSNA experts recommend proceeding conservatively with theranostic treatments until dose limits to normal organs are established.
    March 22, 2024
    Yellow Caution Tape Social
    Page 1 of 81
    Next Page